Who owns Viridian Therapeutics, Inc.\DE?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of VRDN from SEC Form 13F filings across 235 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 235 institutions disclosed 137.3M shares of Viridian Therapeutics, Inc.\DE worth $2.83B — about 127.3% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
235
13F holders
$2.83B
value, 2026 filers
127.3%
of shares outstanding (137.3M sh)
44
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of VRDN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 17.5M | $360.5M | 0.0% | 16.2% | +5.4% |
| 2 | BlackRock, Inc. | 9.3M | $192.1M | 0.0% | 8.6% | +9.1% |
| 3 | Paradigm Biocapital Advisors LP | 8.3M | $170.0M | 3.4% | 7.7% | +22.8% |
| 4 | Bellevue Group AG | 7.1M | $146.4M | 3.0% | 6.6% | +5.6% |
| 5 | Kynam Capital Management, LP | 6.1M | $126.6M | 7.0% | 5.7% | -4.7% |
| 6 | PRICE T ROWE ASSOCIATES INC /MD/ | 5.1M | $105.5M | 0.0% | 4.7% | -10.9% |
| 7 | Fairmount Funds Management LLC | 5.1M | $104.8M | 6.6% | 4.7% | 0.0% |
| 8 | RTW INVESTMENTS, LPNEW | 4.9M | $101.1M | 1.0% | 4.6% | new |
| 9 | STATE STREET CORP | 4.9M | $100.4M | 0.0% | 4.5% | -20.4% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 4.8M | $97.9M | 0.0% | 4.4% | +3.9% |
| 11 | Point72 Asset Management, L.P. | 4.6M | $95.4M | 0.1% | 4.3% | +97.7% |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 3.7M | $76.0M | 0.0% | 3.4% | +18.0% |
| 13 | Venrock Adviser, LLC | 3.3M | $67.1M | 3.3% | 3% | 0.0% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 2.8M | $57.7M | 0.0% | 2.6% | +12.1% |
| 15 | Avoro Capital Advisors LLC | 2.5M | $51.5M | 0.5% | 2.3% | 0.0% |
| 16 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4M | $49.8M | 0.0% | 2.2% | -12.2% |
| 17 | Caligan Partners LP | 2.2M | $45.2M | 2.8% | 2% | 0.0% |
| 18 | GOLDMAN SACHS GROUP INC | 1.9M | $39.9M | 0.0% | 1.8% | +14.6% |
| 19 | CITADEL ADVISORS LLC | 1.9M | $38.8M | 0.0% | 1.7% | +4458.9% |
| 20 | TANG CAPITAL MANAGEMENT LLC | 1.8M | $36.9M | 1.7% | 1.7% | 0.0% |
| 21 | DIMENSIONAL FUND ADVISORS LP | 1.8M | $36.1M | 0.0% | 1.6% | +8.8% |
| 22 | NOVO HOLDINGS A/S | 1.8M | $36.0M | 2.4% | 1.6% | -18.0% |
| 23 | Deep Track Capital, LP | 1.7M | $35.2M | 0.6% | 1.6% | -52.4% |
| 24 | Parkman Healthcare Partners LLC | 1.7M | $34.5M | 3.1% | 1.6% | +21.6% |
| 25 | Candriam S.C.A. | 1.5M | $31.6M | 0.1% | 1.4% | -10.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.